Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system

Pharmacology and Toxicology

Volumn 78, Issue 5, 1996, Pages 348-353

  Luurila, Harri ^a   Olkkola, Klaus T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ZOPICLONE;

ADULT; ALERTNESS; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYSTERESIS; MALE; MODEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SACCADIC EYE MOVEMENT; VOLUNTEER;

EID: 0029974174     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb01387.x     Document Type: Article

References (27)

1. Aantaa, R., M. Salonen & T. Nyrke: Difference in action between oral triazolam and zopiclone. Eur. J. Clin. Pharmacol. 1990, 38, 47-51.
2. Aranko, K,. H. Luurila, J. T. Backman, P. J. Neuvonen & K. T. Olkkola: The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. Brit. J. Clin. Pharmacol. 1994, 38, 363-367.
3. Blanchard, J. C., A. Boireau & L. Julou: Brain receptors and zopiclone. Int. Pharmacopsychiat. 1983, 17, (suppl. 2), 59-69.
4. Chiou, W. L.: The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics. Clin. Pharmacokinet. 1989, 17, 175-199 (part I) & Clin. Pharmacokinet. 1989, 17, 275-290 (part II).
5. Chiou, W. L.: The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics. Clin. Pharmacokinet. 1989, 17, 175-199 (part I) & Clin. Pharmacokinet. 1989, 17, 275-290 (part II).
6. Elie, R & J.-P. Deschenes: Efficacy and tolerance of zopiclone in insomniac geriatric patients. Pharmacology 1983, 27, (suppl. 2), 179-187.
7. Ellinwood, E. H. Jr., D. G. Heatherly, A. M. Nikaido, D. B. Thorir & C. Kilts: Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam diazepam. Psychopharmacology 1985, 86, 392-399.
8. Ellinwood, E. H. Jr., A. M. Nikaido, D. G. Heatherly & T. D. Bjornsson: Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms. Psychopharmacology 1987, 91, 168-174.
9. Fleming, J. A. E., J. Bourgouin & P. Hamilton: A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can. J. Psychiatry 1988, 33, 103-107.
10. Friedman, H., D. J. Greenblatt, G. R. Peters, C. M. Metzler, M. D. Charlton, J. S. Harmatz, E. J. Antal, E. C. Sanborn & S. F. Francom. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol. Therap. 1992, 52, 139-50.
11. Gabrielsson, J. & D. Weiner: Mathematics of parameter estimation. In: Pharmacokinetic/pharmacodynamic data analysis. J. Gabrielson & D. Weiner. Swedish Pharmaceutical Press, Stockholm, Sweden 1994, 9-28.
12. Gibaldi, M. & D. Perrier: Pharmacokinetics. 2nd ed. New York Marcel Dekker, 1982.
13. Goa, K. L. & R. C. Heel: Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986, 32, 48-65.
14. Griffiths, A. N., D. M. Jones & A. Richens: Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam. Brit. J. Clin. Pharmacol. 1986, 21, 647-653.
15. Griffiths, A. N., R. W. Marshall & A. Richens: Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. Brit. J. Clin. Phsrmacol. 1984, 18, 73S-82S.
16. Gumbleton, M., S. Øie & D. Verotta: Pharmacokinetic-pharmacodynamic (PK-PD) modeling in non-steady-state studies and arterio-venous drug concentration differences. Brit. J. Clin. Pharmacol. 1994, 38, 389-400.
17. Holford, N. H. G. & L. B. Sheiner: Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokin. 1981, 6, 429-453.
18. Julou, L., M. C. Bardone, J. C. Blanchard, C. Garret & J. M. Stutzmann: Pharmacological studies of zopiclone. Pharmacology 1983, 27 (suppl. 2), 46-58.
19. Julou, L., J. C. Blanchard & J. F. Dreyfus: Pharmacological and clinical studies of cyclopyrrolones: Zopiclone and suriclone. Pharmacol. Biochem. Bheav. 1985, 23, 653-659.
20. Koopmans, R., J. Dingemanse, M. Danhof, G. P. M. Horsten & C. J. van Boxtel: Pharmcokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system. Clin. Pharmacol. Therap. 1988, 44, 14-22.
21. Le Liboux, A., A. Frydman & J. Gaillot: Simultaneus determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. J. Chromatogr. 1987, 417, 151-158.
22. Marshall R.: The Cardiff Saccade Generation and Analysis System. User's manual. Cardiff, 1989.
23. Mattila, M. J., M. Mattila & P. Tuomainen: Acute pharmacokinetic and pharmacodynamic comparison of two different formulations of temazepam. Med. Biol. 1985, 63, 21-27.
24. Pecknold, J., R. Wilson & P. Le Morvan: Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int. Clin. Psychopharmacology 1990, 5, (Suppl. 2), 57-67.
25. Stone, B. I.: Pencil and paper test-sensitivity to psychotropic drugs. Brit. J. Clin. Pharmacol. 1984, 18, 15S-20S.
26. Trifilletti, R. R. & S. H. Snyder: Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepines. Mol. Pharmacol. 1984, 26, 458-469.
27. Verotta, D., S. L. Beal & L. B. Sheiner: Semiparametric approach to pharmacokinetic-pharmacodynamic data. Amer. J. Physiol. 1989, 256, R1005-R1010.